## FORM 4

Check this box if no longer subject

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-0287	
	Estimated average burg	den	
Filed purpuent to Section 16(a) of the Securities Evolution Act of 1024	hours per response:	0.5	

Ī

	orm 4 or Form 5 continue. See	F	iled pursuant to Section 16(a) of the Securities Exchange Act of 193 or Section 30(h) of the Investment Company Act of 1940	4	Estimated average burden hours per response: 0.5			
1. Name and Addre			2. Issuer Name and Ticker or Trading Symbol <u>GLYCOMIMETICS INC</u> [ GLYC ]	5. Relationship of I (Check all applicat Director X Officer (g below)	10% Owner			
(Last) C/O GLYCOM 9708 MEDICA			3. Date of Earliest Transaction (Month/Day/Year) 12/22/2022	Chief Medical Officer				
			4. If Amendment, Date of Original Filed (Month/Day/Year)		nt/Group Filing (Check Applicable			
(Street) ROCKVILLE	MD	20850			d by One Reporting Person d by More than One Reporting			
(City)	(State)	(Zip)						
		Table I - Non-Deri	ivative Securities Acquired, Disposed of, or Bene	ficially Owned				

1. Title of Security (Instr. 3)	2. Transaction Date	2A. Deemed Execution Date,			4. Securities			5. Amount of Securities	6. Ownership Form: Direct	7. Nature of Indirect
	(Month/Day/Year)	if any (Month/Day/Year)	Code ( 8)	Instr.	5)			Beneficially Owned Following Reported	(D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1100.14)
Common Stock	12/22/2022		Р		110,000	A	<b>\$</b> 2.25 <sup>(1)</sup>	310,000	D	

					I				.,		`				
		Tal	ble II - Derivat (e.g., pı						posed of, convertit			-	d		
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownershij (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisabl	Expiration Date	Title	Amount or Number of Shares				

## Explanation of Responses:

1. The Reporting Person purchased the securities on the open market at purchase prices ranging from \$2.20 to \$2.25 per share, with a weighted average purchase price of \$2.25 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

## Remarks:

## /s/ Brian F. Leaf, attorney-in-12/27/2022 fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.